Therapeutic Advances in Gastroenterology最新文献

{"title":"Prevalence of dysphagia and eosinophilic esophagitis in patients with inflammatory bowel disease or type 2 inflammation: a cross-sectional multicenter screening study.","authors":"Martin Bäuerle, Jurij Maurer, Jagoda Pokryszka, Gottfried Novacek, Christian Primas, Lili Kazemi-Shirazi, Stefanie Dabsch, Adrian Frick, Walter Reinisch, Clemens Dejaco, Michael Trauner, Slagjana Stoshikj, Christine Bangert, Sven Schneider, Stefan Wöhrl, Philipp Schreiner","doi":"10.1177/17562848261470325","DOIUrl":"10.1177/17562848261470325","url":null,"abstract":"<p><strong>Background: </strong>Eosinophilic esophagitis (EoE) is a chronic, type-2 inflammation-driven disease causing dysphagia. Although patients with other type-2 inflammatory diseases (type-2 ID) or inflammatory bowel disease (IBD) may have an increased risk of EoE, there is limited information about the prevalence of EoE in these specific populations.</p><p><strong>Objectives: </strong>This study aims to assess the prevalence of clinically relevant dysphagia as well as underlying EoE in patients with type-2 ID or IBD.</p><p><strong>Design: </strong>This is a cross-sectional, multicenter study of patients with type-2 ID (asthma, rhinosinusitis with polyposis nasi, allergic rhinitis, atopic dermatitis, Immunoglobulin E (IgE)-mediated food allergies) or IBD from the Medical University of Vienna and Floridsdorf Allergy Center.</p><p><strong>Methods: </strong>Patients were screened for esophageal dysphagia using the Brief Esophageal Dysphagia Questionnaire (BEDQ). Relevant dysphagia was defined as a BEDQ score ⩾4, or having a history of bolus impaction or emergency department visit due to dysphagia within the past year. Endoscopy with esophageal biopsies was offered to all patients with relevant dysphagia to screen for EoE.</p><p><strong>Results: </strong>A total of 687 patients (45.9% female, median age 45 years, 53.9% with IBD, 48.5% with a type 2 ID) were screened. Overall, 8.9% (<i>n</i> = 61) reported relevant dysphagia. Endoscopy with biopsies was performed in 22 patients, and 18 patients had undergone endoscopy the year prior to the study. In total, 6 newly diagnosed cases of EoE were observed, while 7 patients had a known history of EoE, resulting in an overall prevalence of 13 patients (1.9%). Patients with any type-2 ID had numerically more EoE (2.7%) than patients with IBD (1.9%).</p><p><strong>Conclusion: </strong>While the prevalence of dysphagia among patients with type-2 ID and IBD may not exceed that of the general population, the prevalence of EoE in these populations may be higher than previously recognized.</p>","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"19 ","pages":"17562848261470325"},"PeriodicalIF":3.8,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13525285/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148857882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined endoscopic ultrasound and conventional endoscopy improves outcomes in bleeding GOV2 and IGV1 gastric varices: A multicenter retrospective propensity-matched cohort study.","authors":"Fangfang Yu, Zhihong Wang, Xuecan Mei, Wei Zhang, Mingkai Chen, Derun Kong","doi":"10.1177/17562848261483777","DOIUrl":"10.1177/17562848261483777","url":null,"abstract":"<p><strong>Background: </strong>Endoscopic ultrasound (EUS)-guided cyanoacrylate injection for gastric varices (GVs) may leave residual untreated vessels due to incomplete visualization of distal collateral channels. Whether adding conventional endoscopic injection improves outcomes remains unclear.</p><p><strong>Objectives: </strong>This multicenter retrospective study evaluated a combined EUS-guided and conventional endoscopic approach in patients with bleeding GOV2 or IGV1 varices.</p><p><strong>Design: </strong>This retrospective study (February 2022-December 2024) included 141 cirrhotic patients with acute gastric variceal bleeding from three Chinese tertiary centers.</p><p><strong>Methods: </strong>Patients received either EUS-guided therapy alone or combined therapy with supplementary conventional endoscopic injection per institutional practice. Propensity score matching (1:1) and multivariable Cox regression were used to reduce selection bias. Primary outcome was variceal rebleeding; secondary outcomes included technical success, variceal recurrence, reintervention, mortality, and adverse events.</p><p><strong>Results: </strong>Technical success was achieved in all patients (100%). After matching, variceal recurrence rates were comparable between groups (5.36% vs. 12.50%, P = 0.185), whereas rebleeding occurred less frequently in the combination group than in the EUS group (7.14% vs. 25.00%, P = 0.010). This association appeared more pronounced in IGV1 varices (2.70% vs. 27.03%, P = 0.016), although the subgroup finding should be interpreted cautiously because the interaction test was not statistically significant. Reintervention was also less frequent in the combination group (12.50% vs. 35.71%, P = 0.004). Mortality and adverse event rates were comparable between groups.</p><p><strong>Conclusion: </strong>Supplementary conventional endoscopic injection after EUS-guided therapy was associated with lower risks of rebleeding and reintervention without an apparent increase in adverse events. This combineds strategy may be a feasible option to improve treatment durability in selected patients with high-risk GOV2 or IGV1 gastric varices, but prospective randomized studies are needed for confirmation.</p>","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"19 ","pages":"17562848261483777"},"PeriodicalIF":3.8,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13525281/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148857790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"All-cause and cause-specific mortality in chronic pancreatitis: A systematic review.","authors":"Yi Jiang, Esther A Adeniran, Wenmo Hu, Yanna Cai, Drew Fletcher, Zijin Lin, Yuan Li, Ali Badaoui, Jianing Li, Judy Tan, Stephen J Pandol","doi":"10.1177/17562848261483780","DOIUrl":"10.1177/17562848261483780","url":null,"abstract":"<p><strong>Background: </strong>Chronic pancreatitis (CP) is a progressive fibroinflammatory disease associated with substantial long-term morbidity. Synthesized evidence on mortality remains limited.</p><p><strong>Objectives: </strong>To systematically review all-cause and cause-specific mortality in adults with CP compared with individuals without CP.</p><p><strong>Design: </strong>This systematic review of observational studies adhered to the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) and Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines.</p><p><strong>Data sources and methods: </strong>We searched PubMed, Web of Science, Embase, Scopus, and Cochrane Central Register of Controlled Trials from database inception to May 29, 2025. Reference list screening, citation tracking, and targeted author- and consortium-based searches were also conducted. Eligible studies included adults with CP that reported mortality outcomes with a non-CP comparator. Data extraction was conducted by one reviewer while another confirmed accuracy. Quality assessment was done by two independent reviewers and conflicts resolved by a third reviewer. Narrative synthesis was done due to high heterogeneity across studies.</p><p><strong>Results: </strong>Of 11,957 records screened through title and abstract, 347 underwent full-text review, and 12 met inclusion criteria. Four additional studies were found through reference list, citation tracking, and targeted searches, yielding a total of 16 included studies with cohort design. Across seven comparative studies, CP was consistently associated with higher all-cause mortality, with standardized mortality ratios ranging from 1.20 to 5.50 and hazard ratios ranging from 1.25 to 5.00. Malignancy was the most frequently reported cause of death. Other causes included cardiovascular, suicide, infectious, liver-related, gastrointestinal, endocrine, renal, respiratory, and accidental.</p><p><strong>Conclusion: </strong>CP is associated with excess all-cause mortality and a broad cause-specific mortality burden extending beyond pancreas-related complications alone. These findings support recognizing CP as a systemic, high-risk chronic disease and highlight the need for more consistent mortality reporting and better-designed studies to clarify which patients are at highest risk.</p><p><strong>Registration prospero: </strong>CRD420251041174.</p>","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"19 ","pages":"17562848261483780"},"PeriodicalIF":3.8,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13525319/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148857772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamic precision therapy in chronic gastrointestinal diseases: A focus on gastroesophageal reflux disease and inflammatory bowel disease-A narrative review and conceptual perspective.","authors":"Yi-Nan Qiu, Bo-Han Zhong, Hui-Hong Zhang, Shi-Xue Dai","doi":"10.1177/17562848261483778","DOIUrl":"10.1177/17562848261483778","url":null,"abstract":"<p><p>Chronic gastrointestinal diseases, including inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), and irritable bowel syndrome (IBS), impose a growing global burden. Their relapsing-remitting nature and variable clinical course challenge the paradigm of long-term continuous therapy, which is associated with adverse effects, poor adherence, and high costs. While dynamic precision therapy (DPT) has emerged as an intuitive solution, its conventional definition-symptom-driven, intermittent drug use-is too narrow and fails to harness the full potential of precision medicine. As a narrative review and perspective article, this paper proposes a paradigm shift by introducing a novel, multidimensional framework for DPT that integrates four synergistic dimensions: symptom-guided relief for acute episodes, disease subtype-guided baseline therapy, pathophysiology-guided dynamic adjustments using biomarkers and smart technologies, and individual patient context-guided shared decision-making. Applying this framework to IBD, GERD, and IBS, we demonstrate how it transforms precision treatment from a simple dosing strategy into a comprehensive platform for precision management. We review cutting-edge tools enabling this vision, from 24-hour pH-impedance monitoring and therapeutic drug monitoring to smart drug delivery systems like MMP-responsive hydrogels. This framework provides a practical guide for transitioning from empirical methods to mechanism-based, patient-centered care, presenting a forward-looking model that could transform future treatment approaches in gastroenterology.</p>","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"19 ","pages":"17562848261483778"},"PeriodicalIF":3.8,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13525278/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148857914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple paths to health: A scoping review of dietary interventions for adults with Crohn's disease and ulcerative colitis.","authors":"Josephine Ingridsdotter, Vedrana Vejzovic, Eva Elmerstig, Klas Sjöberg","doi":"10.1177/17562848261479366","DOIUrl":"https://doi.org/10.1177/17562848261479366","url":null,"abstract":"<p><strong>Background: </strong>Patient and clinical interest in dietary management of inflammatory bowel disease (IBD) is growing, yet a comprehensive overview mapping how dietary interventions are defined, composed, and evaluated across Crohn's disease (CD) and ulcerative colitis (UC) remains scarce.</p><p><strong>Objectives: </strong>This scoping review aims to map current evidence on dietary interventions that may have an impact on the disease course in adults with CD or UC, thereby providing guidance for the design of forthcoming dietary interventions.</p><p><strong>Eligibility criteria: </strong>Included are English articles published between 2000-2025 investigating dietary treatments for adults (+18) reporting on symptoms, remission, or disease activity. Excluded are paediatric studies, single food/supplement-only interventions, and studies combining new medications with diet.</p><p><strong>Sources of evidence: </strong>Systematic searches of PubMed, CINAHL, Scopus, and Web of Science, originally conducted in January 2025 and updated in May 2026, identified 49 eligible studies.</p><p><strong>Charting methods: </strong>Data were charted using Covidence with a form guided by the TIDieR checklist. Dietary composition across interventions was visualised using heatmap analysis.</p><p><strong>Results: </strong>A range of dietary approaches were identified. Most improved patient-reported outcomes and disease activity indices, though a disconnect often persisted between symptomatic relief and inflammatory biomarker normalization. Despite variability even among nominally identical diets, heatmap analysis of diet composition revealed strong consensus around elimination of processed foods and added sugars, alongside emphasis on whole foods, fruits, vegetables, and unsaturated fats.</p><p><strong>Conclusions: </strong>Evidence points toward several possible diets for IBD, and clearly toward the Mediterranean diet and shared whole-food principles as a well-supported, safe, and guideline-endorsed foundation. Next step is designing rigorous research with standardised outcomes, disease-specific populations, mechanistic sub-studies, and the implementation support that adherence requires.</p>","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"19 ","pages":"17562848261479366"},"PeriodicalIF":3.8,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13473801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148762952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment persistence after switching between anti-tumor necrosis factor agents and tofacitinib in ulcerative colitis: A nationwide claims-based cohort study in South Korea.","authors":"Ji Eun Baek, Arum Choi, Han Hee Lee, Bo-In Lee, Kang-Moon Lee","doi":"10.1177/17562848261478114","DOIUrl":"10.1177/17562848261478114","url":null,"abstract":"<p><strong>Background: </strong>The optimal sequencing of advanced therapy in ulcerative colitis (UC) remains unclear. Data comparing different sequencing including the use of tofacitinib as first-line therapy remain scarce.</p><p><strong>Objectives: </strong>We compared the treatment persistence of two therapeutic strategies: anti-tumor necrosis factor (anti-TNF) agents to tofacitinib (A→T) versus tofacitinib to anti-TNF agents (T→A).</p><p><strong>Design: </strong>We conducted a retrospective, nationwide, claims-based cohort study using data from the Korean Health Insurance Review and Assessment database.</p><p><strong>Methods: </strong>We included adult UC patients initiating anti-TNF agents or tofacitinib as first-line therapy. The primary outcome was second-line treatment persistence, using Kaplan-Meier method and multivariable Cox models to estimate adjusted hazard ratios (aHRs). Propensity score matching balanced baseline characteristics.</p><p><strong>Results: </strong>A total of 314 patients were included (A→T, n=273; T→A, n=41). The T→A group was younger (33.0 vs 42.0 years; P=0.02), had lower concomitant use of corticosteroids at first-line therapy (36.59% vs 65.57%; P<0.01), and had shorter duration of total advanced therapy (3.50 vs 4.29 years; P<0.01). After propensity score matching, the persistence of second-line therapy was significantly longer in the A→T group compared with the T→A group (aHR, 2.48; 95% CI, 1.18-5.21; P=0.02), whereas the persistence of first-line therapy did not differ significantly between the two sequences (aHR, 1.18; 95% CI, 0.76-1.85; P=0.46). Progression to third-line therapy occurred more frequently in the T→A group than in the A→T group (41.5% vs 19.8%).</p><p><strong>Conclusion: </strong>In Korean UC patients, switching from anti-TNF agents to tofacitinib was associated with longer second-line treatment persistence than the reverse sequence.</p>","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"19 ","pages":"17562848261478114"},"PeriodicalIF":3.8,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13462500/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148726919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical associations, outcomes, and therapeutic management of patients with symptomatic sclerosing mesenteritis.","authors":"Christina Liava, Danai Chourmouzi, Georgia Gioula, Emmanouil Sinakos, Evangelos Akriviadis","doi":"10.1177/17562848261475954","DOIUrl":"10.1177/17562848261475954","url":null,"abstract":"<p><strong>Background: </strong>Sclerosing mesenteritis (SM) is a rare fibroinflammatory disease of unknown etiology that primarily affects the root of the small bowel mesentery. Associated diseases that contribute to or predispose to the development of SM have not been well-documented.</p><p><strong>Objectives: </strong>We aimed to describe the clinical associations of patients diagnosed with symptomatic SM, their clinical features, outcomes, and therapeutic management.</p><p><strong>Design: </strong>We performed a prospective cohort study from 2014 to 2025.</p><p><strong>Methods: </strong>Eligible patients were those aged ≥ 18 years who presented at two tertiary Medical Centers in Greece with SM-specific symptoms after ruling out other causes of abdominal pain and radiographic signs indicative of the Coulier criteria on computed tomography scans (<i>N</i>=58). SM cases lost to follow-up were excluded (<i>n</i>=3). Descriptive statistics and comparative statistical analysis were used.</p><p><strong>Results: </strong>In total, 55 patients with symptomatic SM were included, of whom 25.5% developed severe intra-abdominal complications, with even fatal outcomes. Colchicine in combination with corticosteroid tapering was the most frequently administered therapy (47.3%). SM improved in most patients after treatment (72.9%). During the disease course, 23.6% of patients were diagnosed with immunoglobulin G4-related disease (IgG4-RD), 9.1% had co-existing systemic autoimmune rheumatic diseases, and 9.1% were diagnosed with an abdominal/pelvic malignancy within 6 months of initial SM presentation. In the remaining cases (58.2%), an association with metabolic syndrome conditions and excessive accumulation of visceral adipose tissue was observed.</p><p><strong>Conclusion: </strong>In this prospective cohort study, we identified a correlation of symptomatic SM with chronic inflammatory diseases. Certain SM cases are probably part of the IgG4 disease spectrum or systemic autoimmune rheumatic diseases. These results should be taken into account when consulting patients with symptomatic SM, as the clinical management, prognosis, and therapeutic approach may differ according to the underlying systemic disorder.</p>","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"19 ","pages":"17562848261475954"},"PeriodicalIF":3.8,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13438346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148680621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: \"Preliminary research on the effectiveness and safety of metal clip-assisted endoscopic variceal ligation in the treatment of gastric varices\".","authors":"Jake Krige, Sandie Thomson","doi":"10.1177/17562848261475955","DOIUrl":"10.1177/17562848261475955","url":null,"abstract":"","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"19 ","pages":"17562848261475955"},"PeriodicalIF":3.8,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13434924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148674489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary diffusion abnormalities in patients with inflammatory bowel disease: A longitudinal study.","authors":"Hugo Maisonneuve, Benedicte Caron, Anne Guillaumot, Mathias Poussel, David Sorel, François Chabot, Bruno Ribeiro Baptista, Laurent Peyrin-Biroulet, Ari Chaouat, Simon Valentin","doi":"10.1177/17562848261475935","DOIUrl":"10.1177/17562848261475935","url":null,"abstract":"<p><strong>Background: </strong>Impaired diffusing capacity of the lung for carbon monoxide (DL_CO) has been frequently described among patients with inflammatory bowel diseases, but longitudinal data of DL_CO impairment and its association with IBD activity remain unclear.</p><p><strong>Objectives: </strong>To describe the longitudinal report of prevalence and clinical characteristics of chronic DL_CO impairment among patients with IBD reporting respiratory symptoms.</p><p><strong>Design: </strong>We conducted a prospective single-center study including consecutive patients with confirmed IBD and respiratory symptoms.</p><p><strong>Methods: </strong>Patients underwent longitudinal evaluation with chest CT scans and pulmonary function tests.</p><p><strong>Results: </strong>Among 75 patients with DL_CO measurements, 12 (16%) showed persistently reduced DL_CO over a median follow-up of 26.9 [IQR 24.9-30.6] months. Median DL_CO was 63.4% of predicted value. All patients had mild or inactive IBD and were on biologics. Imaging abnormalities were mild and did not explain the DL_CO reduction.</p><p><strong>Conclusions: </strong>Chronic DL_CO impairment was observed in 16.0% of IBD patients and no obvious association with clinically active IBD was observed in this selected symptomatic cohort.</p>","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"19 ","pages":"17562848261475935"},"PeriodicalIF":3.8,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13434094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148674550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IOIBD: the International Organization for the Study of Inflammatory Bowel Disease.","authors":"Iris Dotan, Marla C Dubinsky, Corey A Siegel, James Lindsay, Dermot McGovern, Matthieu Allez, Pär Myrelid, James Lewis, Bruce E Sands, Laurent Peyrin-Biroulet, Silvio Danese, Vineet Ahuja, Gilaad G Kaplan, Marischka Konings, Richard Gearry, Siew C Ng, Vipul Jairath, Fernando Magro, Mark S Silverberg, Dan Turner, Maria T Abreu, Ailsa Hart, Axel Dignass, David T Rubin","doi":"10.1177/17562848261470923","DOIUrl":"10.1177/17562848261470923","url":null,"abstract":"<p><p>The International Organization for the Study of Inflammatory Bowel Disease (IOIBD) is an international scientific organization that has shaped the framework for inflammatory bowel disease (IBD) research, clinical management strategy, therapeutic development, and clinical trial methodology for more than four decades. Formally constituted in April 1981 in Lyon, France, IOIBD was created to address fundamental barriers to scientific and clinical progress in IBD, including inconsistent definitions of disease activity and outcomes across studies and countries. Since the establishment of the IOIBD Foundation for Research and Education in 1997, IOIBD has combined a highly engaged global membership of experts with structured governance, continuously active thematic clusters, and an annual rotating international meeting to deliver consensus frameworks and collaborative initiatives that translate directly to clinical practice and regulatory and translational science. Key outputs include studies of global epidemiology of IBD, the Selecting Therapeutic Targets in IBD (Selecting Therapeutic Targets in Inflammatory Bowel Disease, STRIDE) treat-to-target programs; the SPIRIT consensus initiative addressing long-term disease impact and endpoints for disease-modification trials; validated approaches to capturing disability and patient-reported outcomes; consensus guidance on nutrition and diet as modifiable and potentially disease-modifying factors; recommendations to optimize IBD clinical trial design and endpoints; reclassification of IBD initiative; rapid international guidance during the COVID-19 pandemic; and educational initiatives including topic-focused satellite symposia, the Helmsley-IOIBD Clinical Experience Exchange Program, and the Empowering Women in IBD Leadership Program (EMPOWHER). This manuscript reviews IOIBD's history, operational model, selected scientific contributions, educational mission, and evolving strategy as the field moves toward precision medicine, globalization of care, and data-intensive approaches, including artificial intelligence.</p>","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"19 ","pages":"17562848261470923"},"PeriodicalIF":3.8,"publicationDate":"2026-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13434103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148674504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}